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Background: As a potent anticoagulant agent, apixaban exposes to a risk of bleeding. An effective way to reverse its effects is needed. Objectives 
were to study efficacy and safety of recombinant activated factor VII (rFVIIa), prothrombin complex concentrate (PCC) and fibrinogen concentrate to 
reverse the anticoagulant effect of apixaban in a rabbit model of bleeding and thrombosis.
Methods: First, a dose ranging study assessed the minimal apixaban dose that increased bleeding. Then, 63 anaesthetized and ventilated 
rabbits were randomized into 5 groups: control (saline), apixaban (apixaban and saline), rFVIIa (apixaban and rFVIIa), PCC (apixaban and PCC) 
and fibrinogen (apixaban and fibrinogen). The Folts model was applied: a stenosis and an injury were carried out on the carotid artery, inducing 
thrombosis, detected as cyclic flow reductions, which were recorded over 20 minutes. Then the following were measured: ear immersion bleeding 
time, clotting times, anti-Xa activity, thrombelastometric parameters and thrombin generation test (TGT). Ultimately, a hepatosplenic section was 
performed and the total amount of blood loss after 15 min was evaluated as primary end point.
Results: Apixaban increased blood loss (12[9-14]g vs. 8[5,5-11]g for control (median [range]), p<0.0003), lengthened ear bleeding time, 
Prothrombin Time (PT), thrombelastographic clotting time and decreased thrombin generation. rFVIIa decreased ear bleeding time (81[70-100]
s vs 118[106-154]s, p<0.05), but without efficacy on blood loss. PCC and rFVIIa decreased PT as well as thrombelastographic clotting time and 
shortened the lag time in TGT. Fibrinogen concentrate, surprisingly, increased blood loss and BT whereas it improved thromboelastographic clot 
firmness and increased thrombin generation to supraphysiological levels. Regarding safety, neither rFVIIa, PCC nor fibrinogen concentrate increased 
cyclic flow reductions.
Conclusion: rFVIIa, PCC and fibrinogen concentrate improved laboratory parameters, but did not reverse apixaban induced-bleeding.
